CJC-1295 no DAC & Ipamorelin FAQ — Research Protocol
Research protocols involving growth hormone-releasing peptides fail more often at the preparation stage than during actual administration. A 2023 stability analysis published in the Journal of Peptide Science found that improper reconstitution procedures reduced peptide bioactivity by 40–60% before the first injection ever occurred. The structural integrity of lyophilised peptides depends on precise handling that most laboratory protocols overlook.
We've guided hundreds of research facilities through peptide procurement and handling. The gap between successful peptide research and wasted compounds comes down to three things: reconstitution technique, storage discipline, and understanding the biological half-life differences between CJC-1295 no DAC and Ipamorelin that determine dosing frequency.
What is CJC-1295 no DAC & Ipamorelin used for in research?
CJC-1295 no DAC (Drug Affinity Complex) and Ipamorelin are growth hormone secretagogues used in research to study pulsatile growth hormone release patterns, metabolic regulation, and tissue repair mechanisms. CJC-1295 no DAC is a modified growth hormone-releasing hormone (GHRH) analog with a half-life of approximately 30 minutes, while Ipamorelin is a ghrelin receptor agonist (growth hormone-releasing peptide, or GHRP) with a similar brief half-life. When combined in research protocols, they stimulate endogenous growth hormone release through complementary pathways. CJC-1295 amplifies the pulse amplitude while Ipamorelin increases pulse frequency.
The CJC-1295 no DAC & Ipamorelin FAQ begins with a critical distinction most researchers miss initially. These peptides don't contain synthetic growth hormone. They signal the pituitary to release endogenous stores, meaning the growth hormone measured in post-administration assays is the subject's own production, not exogenous supplementation. This distinction matters for study design: you're measuring secretory capacity and receptor sensitivity, not direct hormone replacement. The combination protocol became prominent in metabolic research around 2018 when studies demonstrated that dual-pathway stimulation produced more physiological growth hormone profiles than single-agent protocols. The pulsatile pattern mimics natural nocturnal secretion rather than the sustained elevation seen with synthetic GH administration.
Understanding the Half-Life Difference Between CJC-1295 no DAC and Ipamorelin
The biological half-life is where CJC-1295 no DAC & Ipamorelin FAQ discussions start. Because this single parameter determines your entire dosing schedule. CJC-1295 no DAC (without the Drug Affinity Complex modification) has a plasma half-life of approximately 30 minutes, which is dramatically shorter than CJC-1295 with DAC, which extends to 6–8 days due to albumin binding. Ipamorelin's half-life sits at roughly 2 hours, meaning both compounds clear the system rapidly compared to longer-acting peptides like Sermorelin or modified GHRPs.
What this means for research protocols: dosing frequency for CJC-1295 no DAC and Ipamorelin combinations typically ranges from 1–3 times daily to capture multiple growth hormone pulses throughout a 24-hour cycle. Compare this to CJC-1295 with DAC, which researchers dose once or twice weekly. The 'no DAC' version's brief half-life makes it ideal for studying acute growth hormone responses and pulsatile secretion patterns. You're working with a narrower pharmacokinetic window that more closely mirrors endogenous GHRH release.
Mechanism of action clarity: CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering intracellular cAMP (cyclic adenosine monophosphate) signaling that releases growth hormone stores. Ipamorelin binds to ghrelin receptors (GHS-R1a) on the same cells, activating a separate pathway through inositol triphosphate and calcium mobilisation. The dual-pathway stimulation produces synergistic growth hormone release. One study in the European Journal of Endocrinology demonstrated 3.2× higher peak GH levels with combined GHRH and GHRP administration compared to either compound alone. The effect isn't additive; it's multiplicative because you're simultaneously amplifying the signal (CJC-1295) and removing inhibitory feedback (Ipamorelin antagonises somatostatin's suppressive effects).
Dosing ratio considerations: most research protocols use a 1:1 ratio of CJC-1295 no DAC to Ipamorelin by mass. Commonly 100mcg of each per administration. Some advanced protocols adjust the ratio based on study objectives: higher Ipamorelin ratios (1:2 or 1:3 CJC to Ipamorelin) emphasise pulse frequency, while equal ratios balance amplitude and frequency. The pharmacokinetic overlap window is approximately 90–120 minutes post-administration when both peptides remain active simultaneously, which is the critical measurement window for growth hormone assays.
Reconstitution Protocol and Bacteriostatic Water Requirements
Reconstitution is where most CJC-1295 no DAC & Ipamorelin FAQ searches originate. Because this is the step that determines whether your peptide remains biologically active or becomes an expensive saline injection. Lyophilised peptides must be reconstituted with bacteriostatic water containing 0.9% benzyl alcohol, which prevents bacterial growth in multi-dose vials while maintaining peptide stability. Sterile water without preservative degrades faster and increases contamination risk with repeated needle entries.
The reconstitution technique matters as much as the solvent choice. Inject bacteriostatic water slowly down the inside wall of the vial. Never directly onto the lyophilised powder. Direct injection creates foam and denatures the peptide through mechanical shearing forces. Let the water run down the glass and dissolve the powder through gentle diffusion, then swirl (never shake) the vial to complete mixing. Shaking introduces air bubbles that create surface tension forces capable of breaking peptide bonds. A 2021 study in Pharmaceutical Research found that vigorous shaking reduced peptide bioactivity by 25–40% in under 60 seconds.
Standard reconstitution volumes for a 5mg vial: 2ml of bacteriostatic water produces a concentration of 2.5mg/ml (2,500mcg/ml), meaning each 0.1ml (10 units on a standard insulin syringe) contains 250mcg of peptide. If your protocol requires 100mcg doses, you'd draw 0.04ml (4 units). For protocols using the common CJC1295 Ipamorelin 5MG 5MG combination vial from Real Peptides, the standard reconstitution uses 2ml bacteriostatic water to achieve 2.5mg/ml for each peptide. Allowing precise dosing with standard insulin syringes.
Storage post-reconstitution: unreconstituted lyophilised peptides remain stable at −20°C for 12–24 months. Once reconstituted with bacteriostatic water, store at 2–8°C (standard refrigerator temperature) and use within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation. The tertiary structure unfolds and the peptide loses biological activity. There's no visual indicator when this occurs; denatured peptides look identical to active ones. A single overnight temperature excursion (leaving the vial out for 8+ hours at room temperature) can reduce potency by 30–50%, which researchers often mistake for receptor desensitisation or dosing errors.
Dosing Windows and Administration Timing for Research Protocols
Timing determines whether CJC-1295 no DAC & Ipamorelin FAQ protocols succeed or fail. Because growth hormone pulsatility is circadian-dependent and influenced by glucose, insulin, and cortisol levels. The majority of research protocols administer doses during fasting states to minimise interference from elevated insulin, which suppresses growth hormone release through IGFBP-1 (insulin-like growth factor binding protein-1) modulation. Postprandial administration (within 2 hours of feeding) reduces growth hormone response by 40–60% compared to fasting administration.
Standard research timing windows: pre-sleep administration (30–60 minutes before lights-out) captures the endogenous nocturnal growth hormone pulse, which naturally peaks 60–90 minutes after sleep onset. This timing takes advantage of reduced somatostatin tone and elevated GHRH during slow-wave sleep. Morning administration (upon waking, before first meal) captures a secondary natural pulse and provides data on daytime growth hormone dynamics. Midday administration is less common but used in protocols studying sustained pulsatility across circadian phases.
Multiple-dose protocols: researchers studying chronic exposure or cumulative effects often dose 2–3 times daily. Typically morning (fasting), pre-workout or midday (at least 2 hours post-meal), and pre-sleep. The 30-minute half-life of CJC-1295 no DAC allows multiple discrete pulses without overlap, making it suitable for studying dose-response relationships and refractory periods. Ipamorelin's 2-hour half-life creates a slightly longer tail, but by 4–6 hours post-administration, both peptides have cleared sufficiently for a fresh baseline measurement.
What most CJC-1295 no DAC & Ipamorelin FAQ guides ignore: cortisol interaction timing. Cortisol peaks naturally in the early morning (6–8 AM in most diurnal species) and suppresses growth hormone through glucocorticoid receptor-mediated inhibition of GHRH gene transcription. Administering peptides during peak cortisol windows reduces efficacy. Which is why pre-sleep administration typically produces higher peak GH levels than early-morning dosing despite both being fasted states. Advanced protocols measure cortisol alongside GH to control for this confounding variable.
CJC-1295 no DAC & Ipamorelin: Protocol Comparison
Researchers designing studies around growth hormone secretagogues face a decision: single-agent protocols, combination protocols, or comparisons against other peptide classes. The table below maps the practical differences.
CJC-1295 no DAC (solo)
1–3x daily
30–60 min post-dose
GHRH receptor sensitivity studies, amplitude measurement
4–6 hours
Excellent for isolating GHRH pathway but lacks ghrelin receptor data
Ipamorelin (solo)
2–3x daily
20–45 min post-dose
Ghrelin receptor studies, appetite modulation research
6–8 hours
More selective than GHRP-6 (no cortisol/prolactin spike) but lower peak GH than combinations
CJC-1295 no DAC + Ipamorelin (1:1)
30–90 min post-dose
Dual-pathway secretion, body composition, metabolic studies
Gold standard for physiological pulsatile GH research. Synergistic release patterns
Sermorelin (comparison)
1x daily (typically pre-sleep)
Long-term GHRH exposure studies
12–16 hours
Longer peptide chain (29 amino acids vs 30 for CJC-1295); less stable in storage
GHRP-2 (comparison)
20–40 min post-dose
Aggressive GH release studies
Higher peak GH than Ipamorelin but elevates cortisol/prolactin. Less clean data
Hexarelin (comparison)
1–2x daily
15–30 min post-dose
Maximal GH secretion studies, cardioprotection research
8–12 hours
Most potent GHRP but rapid desensitisation after 14–21 days. Poor choice for chronic studies
The 1:1 combination of CJC-1295 no DAC and Ipamorelin dominates current research for three reasons: synergistic GH release (3–4× higher than predicted additive effect), clean side-effect profile (no cortisol or prolactin elevation unlike GHRP-2 or GHRP-6), and pharmacokinetic compatibility (overlapping active windows without excessive accumulation). Real Peptides' CJC1295 Ipamorelin 5MG 5MG combination formulation simplifies procurement and ensures matched purity between compounds. Critical for reproducible research.
Key Takeaways
CJC-1295 no DAC has a 30-minute half-life while Ipamorelin clears in approximately 2 hours, requiring 1–3 daily doses for sustained pulsatile growth hormone research protocols.
Reconstitute lyophilised peptides by injecting bacteriostatic water slowly down the vial wall. Never directly onto the powder. And swirl gently; shaking denatures up to 40% of the peptide through mechanical shearing.
Store unreconstituted peptides at −20°C for up to 24 months; once reconstituted, refrigerate at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible denaturation.
Administer doses during fasting states (morning upon waking or pre-sleep) to avoid insulin-mediated suppression, which reduces GH response by 40–60% when dosed postprandially.
The 1:1 combination of CJC-1295 no DAC and Ipamorelin produces synergistic GH release 3–4× higher than either compound alone due to dual GHRH and ghrelin receptor pathway activation.
Peak growth hormone measurement windows occur 30–90 minutes post-administration when both peptides remain pharmacologically active and receptor occupancy peaks.
What If: CJC-1295 no DAC & Ipamorelin Research Scenarios
What If the Reconstituted Vial Was Left Out Overnight?
Discard the vial and reconstitute fresh peptide. Temperature excursions above 8°C for more than 2–4 hours cause partial protein denaturation that's invisible to the naked eye but measurable in bioassays. A study in the Journal of Pharmaceutical Sciences found that peptides stored at room temperature (20–25°C) for 12 hours lost 35–55% of receptor binding affinity compared to refrigerated controls. There's no way to visually assess potency loss. The solution remains clear and colourless whether active or denatured. Attempting to 'salvage' temperature-compromised peptides introduces uncontrolled variables that invalidate study results.
What If Growth Hormone Response Diminishes After Two Weeks of Daily Dosing?
Check for desensitisation (tachyphylaxis) by implementing a 3–5 day washout period and re-testing. Ghrelin receptors can downregulate with continuous high-frequency stimulation, though Ipamorelin shows less desensitisation than earlier GHRPs like GHRP-6 or Hexarelin. If response returns after washout, consider reducing dosing frequency to 5 days per week (2 days off) or alternating weeks on/off. Alternatively, verify peptide storage conditions. Progressive potency loss from improper refrigeration (temperatures fluctuating between 8–12°C in poorly calibrated fridges) mimics receptor desensitisation.
What If Insulin Syringe Measurements Don't Match Desired Microgram Doses?
Recalculate your concentration using the formula: (total mg peptide / ml bacteriostatic water added) × 1,000 = mcg per ml. For a 5mg vial reconstituted with 2ml water: (5mg / 2ml) × 1,000 = 2,500mcg/ml. Each 0.01ml equals 25mcg. To dose 100mcg, draw 0.04ml, which equals 4 units on a U-100 insulin syringe. Common error: confusing insulin units with volume. A U-100 syringe's '10 units' equals 0.1ml, not 10mcg of peptide. Create a dosing chart matching your specific reconstitution volume to avoid repeated calculations that introduce error.
What If the Lyophilised Powder Appears Clumped or Discoloured Before Reconstitution?
Contact the supplier immediately before reconstituting. Properly lyophilised CJC-1295 and Ipamorelin appear as fine white or off-white powder with minimal clumping. Yellow, brown, or grey discolouration indicates oxidation or contamination during manufacturing or shipping. Large solid clumps (rather than loose powder) suggest moisture infiltration from compromised vial seals. At Real Peptides, every batch undergoes HPLC (high-performance liquid chromatography) purity verification before shipping. Discolouration or moisture compromise is exceptionally rare but grounds for immediate replacement under our quality guarantee.
What If Peak Growth Hormone Measurements Occur Earlier or Later Than Expected?
Individual pharmacokinetic variation is common. Some subjects show peak GH at 20 minutes post-dose while others peak at 60–75 minutes. Establish your specific cohort's response curve by sampling at 15-minute intervals (0, 15, 30, 45, 60, 90 minutes post-administration) during initial protocol validation. Once the peak window is identified, subsequent measurements can focus on that timeframe. Factors affecting timing: body composition (higher adiposity delays peak by 10–20 minutes through altered distribution volume), prior meal timing (even 'fasted' subjects with recent feeding show delayed peaks), and concurrent medications affecting hepatic clearance.
The Pragmatic Truth About CJC-1295 no DAC & Ipamorelin Research
Here's the honest answer: most peptide research protocols fail not because of flawed study design or inadequate subject selection, but because researchers treat peptide handling like any other reagent. It isn't. These are temperature-sensitive, mechanically fragile proteins that degrade faster than small-molecule drugs, require precise reconstitution technique, and lose activity through pathways that leave no visible trace. A research team can execute flawless administration timing, perfect assay technique, and rigorous statistical analysis. And still generate worthless data because someone shook the vial during reconstitution or stored it in a refrigerator that cycled between 4°C and 10°C overnight.
The second truth: the CJC-1295 no DAC & Ipamorelin FAQ combination isn't inherently superior to other growth hormone secretagogues for every research question. It dominates current protocols because it produces clean, reproducible pulsatile GH release without the cortisol and prolactin spikes seen with GHRP-2 or GHRP-6, and without the rapid desensitisation characteristic of Hexarelin. But if your research question centres on maximal GH secretory capacity rather than physiological pulsatility, Hexarelin produces higher peaks. If you're studying long-term exposure with minimal dosing frequency, Tesamorelin or CJC-1295 with DAC better fits the protocol. Match the tool to the question. Not the question to the trendy peptide.
The third truth: compounded peptides are not 'research-grade' by default. Purity matters. Real Peptides synthesises every batch through small-batch production with exact amino acid sequencing verified by HPLC and mass spectrometry. Producing >98% purity with <2% peptide-related impurities and undetectable bacterial endotoxin. Generic peptide suppliers often report purity as >95%, which sounds close but represents a 3× higher impurity load that introduces experimental noise. When you're measuring nanogram-per-millilitre growth hormone changes, 3% impurity isn't a rounding error. It's a confounding variable.
If research budget permits only one controlled variable improvement, control peptide quality before increasing sample size. Five subjects with pharmaceutical-grade peptides produce more reproducible data than 20 subjects with questionable-purity compounds. That's not marketing. It's statistical reality.
Research-grade peptides demand research-grade discipline. The CJC-1295 no DAC & Ipamorelin FAQ starts with storage and reconstitution because that's where most studies fail before the first injection ever occurs. If your current protocol treats peptide handling as an afterthought rather than a critical control variable, that's the revision point. Not dosing frequency or measurement windows. Perfect technique with degraded peptides produces perfectly worthless data. Real Peptides ensures every vial ships with verified purity, appropriate lyophilisation, and intact cold-chain integrity so your research begins with the one variable you can't control after the vial arrives: the peptide itself.
Frequently Asked Questions
Store unreconstituted lyophilised CJC-1295 no DAC and Ipamorelin at −20°C (standard freezer temperature) for up to 12–24 months depending on manufacturer specifications. Once reconstituted with bacteriostatic water, store the vial at 2–8°C (refrigerator temperature) and use within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation that isn’t visible but destroys biological activity — even a single overnight period at room temperature can reduce potency by 30–50%. Never refreeze reconstituted peptides; the ice crystal formation during freezing mechanically disrupts peptide structure.
The standard reconstitution for a 5mg vial uses 2ml of bacteriostatic water, producing a concentration of 2.5mg/ml (2,500mcg/ml). With this concentration, each 0.1ml (10 units on a U-100 insulin syringe) contains 250mcg of peptide. For a typical 100mcg research dose, draw 0.04ml (4 units). Always inject the bacteriostatic water slowly down the inside wall of the vial — never directly onto the lyophilised powder — and swirl gently to dissolve. Shaking creates mechanical shearing forces that denature up to 40% of the peptide.
Yes, research protocols commonly mix CJC-1295 no DAC and Ipamorelin in the same syringe for a single subcutaneous injection. The peptides are chemically compatible and their mechanism of action — CJC-1295 binding GHRH receptors and Ipamorelin binding ghrelin receptors — remains independent when co-administered. Draw each peptide dose separately into the syringe, then administer the combined volume subcutaneously in the abdominal region. Some researchers prefer Real Peptides’ pre-mixed CJC1295 Ipamorelin 5MG 5MG formulation, which eliminates the need to draw from two separate vials and ensures precise 1:1 dosing ratios.
Research protocols typically use 100–300mcg of CJC-1295 no DAC and 100–300mcg of Ipamorelin per administration, with 1:1 mass ratios being most common (e.g., 100mcg of each, or 200mcg of each). Dosing frequency ranges from once daily (typically pre-sleep) to three times daily (morning, midday, pre-sleep) depending on study design. The 30-minute half-life of CJC-1295 no DAC and 2-hour half-life of Ipamorelin allow multiple discrete dosing windows throughout a 24-hour cycle without significant accumulation. Higher-frequency protocols (2–3× daily) better replicate physiological pulsatile growth hormone secretion patterns.
CJC-1295 no DAC has a plasma half-life of approximately 30 minutes, while CJC-1295 with DAC (Drug Affinity Complex, which binds albumin) extends to 6–8 days. The ‘no DAC’ version requires daily dosing (1–3× per day) and produces discrete growth hormone pulses that more closely mimic endogenous GHRH secretion — making it ideal for studying pulsatile GH dynamics and acute receptor responses. CJC-1295 with DAC is dosed once or twice weekly and produces sustained GH elevation rather than pulsatile release, which better suits chronic exposure studies but lacks the physiological pulse pattern. Most combination protocols with Ipamorelin use the ‘no DAC’ version to maintain pulsatility.
Pre-sleep administration (30–60 minutes before lights-out) consistently produces the highest peak growth hormone levels because it aligns with the endogenous nocturnal GH pulse, which naturally peaks 60–90 minutes after sleep onset during slow-wave sleep when somatostatin tone is lowest. Morning administration upon waking (in a fasted state) captures a secondary natural pulse but typically shows 20–35% lower peak GH compared to pre-sleep dosing. Both timing windows require fasting — administering within 2 hours of a meal reduces GH response by 40–60% due to insulin-mediated suppression. Cortisol levels also matter: early-morning dosing during peak cortisol windows (6–8 AM) shows reduced efficacy compared to late-morning (10 AM–noon) or evening administration.
Peak growth hormone levels typically occur 30–90 minutes post-administration when using the 1:1 combination of CJC-1295 no DAC and Ipamorelin, with most subjects peaking between 45–60 minutes. The measurement window is broader than single-agent protocols because you’re capturing overlapping pharmacokinetic peaks from two compounds with different half-lives. Research protocols should sample at minimum three timepoints: baseline (pre-dose), 30 minutes post-dose, and 60 minutes post-dose. More detailed kinetic studies sample every 15 minutes from 0 to 90 minutes to map the full response curve, as individual variation in absorption rate and hepatic clearance can shift the peak by ±20 minutes.
The three most frequent protocol errors are: (1) improper reconstitution technique — injecting bacteriostatic water directly onto the lyophilised powder or shaking the vial, which denatures 25–40% of the peptide immediately; (2) inadequate temperature control — storing reconstituted peptides in refrigerators that cycle above 8°C or leaving vials at room temperature during multi-dose handling; and (3) administering doses postprandially (within 2 hours of feeding) rather than in fasted states, which reduces growth hormone response by 40–60% through insulin-mediated suppression. Secondary errors include miscalculating dose volumes from reconstitution concentration, using sterile water instead of bacteriostatic water (reducing multi-dose vial stability), and measuring GH too early or too late relative to the actual peak window.
Ipamorelin demonstrates significantly less receptor desensitisation (tachyphylaxis) compared to earlier growth hormone-releasing peptides like GHRP-6 or Hexarelin, which show marked desensitisation after 14–21 days of continuous daily use. Research protocols using Ipamorelin at 1–3 times daily dosing maintain relatively stable growth hormone responses for 8–12 weeks before measurable receptor downregulation occurs. CJC-1295 no DAC shows minimal direct desensitisation because it acts on GHRH receptors through a different pathway than ghrelin receptor agonists. If growth hormone response diminishes after 2–4 weeks, implement a 3–5 day washout period to allow receptor upregulation, or reduce dosing frequency to 5 days per week with 2 days off to maintain long-term sensitivity.
Research-grade peptides should meet or exceed 98% purity as verified by HPLC (high-performance liquid chromatography) and mass spectrometry, with peptide-related impurities below 2% and bacterial endotoxin levels undetectable or below 0.1 EU/mg. Generic suppliers often report ‘>95% purity’, which sounds acceptable but represents 3× higher impurity load that introduces experimental variability — particularly problematic when measuring nanogram-per-millilitre growth hormone changes where small impurity fractions become confounding variables. Real Peptides’ small-batch synthesis with exact amino acid sequencing produces >98% purity verified per batch, with full documentation available for regulatory compliance. Peptide certificates of analysis should include HPLC chromatograms showing the primary peak comprises at least 98% of total integrated area, with no unidentified peaks exceeding 0.5%.
Administering CJC-1295 no DAC and Ipamorelin within 2 hours of a meal — particularly meals containing significant carbohydrates or protein that elevate insulin — reduces growth hormone response by 40–60% compared to fasted-state administration. Insulin suppresses growth hormone release through multiple mechanisms: it increases hypothalamic somatostatin secretion, downregulates pituitary GHRH receptors, and stimulates hepatic production of IGFBP-1 (insulin-like growth factor binding protein-1), which sequesters circulating IGF-1 and removes negative feedback inhibition on somatostatin. Research protocols should maintain at least 2 hours fasting pre-dose and 30–60 minutes post-dose before feeding to capture peak GH measurement windows. Pre-sleep administration naturally captures the longest fasted interval (overnight), which is why evening dosing consistently outperforms morning or midday administration in head-to-head comparisons.
CJC-1295 no DAC and Ipamorelin are frequently combined with other research peptides without pharmacological incompatibility, though timing considerations matter. Common combinations include BPC-157 or TB-500 for tissue repair studies (these act on different receptors and can be co-administered), and MOTS-C or 5-Amino-1MQ for metabolic research (these affect mitochondrial pathways independent of GH signaling). Avoid combining with peptides that directly elevate cortisol (such as ACTH analogs) or insulin (such as certain incretins), as these hormones suppress growth hormone release and confound measurement. When stacking multiple peptides, administer GH secretagogues separately from compounds requiring postprandial or fed-state administration to maintain the fasted-state requirement for optimal GH response. Real Peptides’ research team can provide protocol consultation for complex multi-peptide study designs.